Checkpoint inhibitor-related renal vasculitis and use of rituximab
The percentage of patients with cancer eligible for checkpoint inhibitor (CPI) therapy has increased rapidly over the past few years and approaches 45%. As a result, more cases of CPI-related nephrotoxicity, including a rare subset with vasculitis, are being reported. To elucidate the clinical prese...
Tallennettuna:
| Päätekijät: | , , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BMJ Publishing Group
2020-10-01
|
| Sarja: | Journal for ImmunoTherapy of Cancer |
| Linkit: | https://jitc.bmj.com/content/8/2/e000750.full |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|